Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa

Background Rifampicin induces expression of the cytochrome P450 isoenzyme 2B6 (CYP2B6), which metabolizes efavirenz. The CYP2B6 516G>T polymorphism impairs efavirenz metabolism and occurs more commonly in Africans than in Caucasians. We explored the effect of rifampicin-based antitubercular therapy and the 516G>T polymorphism on efavirenz concentrations in HIV- infected patients in South Africa. Methods Between-patient and within-patient comparisons were made of mid-dosing interval efavirenz plasma concentrations in adults on antiretroviral therapy including efavirenz 600 mg daily, with and without antitubercular therapy. Results There were 142 participants (40 were on antitubercular therapy and 102 were controls), the mean weight was 66 kg. Median efavirenz concentration was 2.4 mg/l (interquartile range [IQR] 1.3–3.1) and 1.8 mg/l (IQR 1.4–4.4) in participants on antitubercular therapy and controls, respectively (P=0.734). Paired efavirenz concentrations during and after antitubercular therapy in 17 participants were also similar (P=0.113). Genotyping results were 60 (49%) G/G homozygotes, 46 (38%) G/T heterozygotes and 16 (13%) T/T homozygotes. In a multivariate logistic regression model adjusted for sex, weight and concomitant antitubercular therapy, the 516G>T polymorphism was strongly associated with high (>4 mg/l) efavirenz concentrations: odds ratio (OR) 4.4 (95% confidence interval [CI] 1.3–14.9) for G/T versus G/G and 31.1 (95% CI 6.6–146.6) for T/T versus G/G. High efavirenz concentrations were associated with severe sleep disturbance (P=0.048). Low (<1 mg/l) efavirenz concentrations were associated with virological failure (OR 12.5, 95% CI 2.7–57.3). Conclusions Efavirenz can be used together with rifampicin-based antitubercular therapy without dose adjustment in this population. The 516G>T polymorphism occurred commonly and was associated with high efavirenz concentrations.

[1]  T. Tenhave,et al.  Slow efavirenz metabolism genotype is common in Botswana. , 2008, Journal of acquired immune deficiency syndromes.

[2]  G. Maartens,et al.  Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. , 2008, JAMA.

[3]  Prosper Chonzi,et al.  High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe , 2008, European Journal of Clinical Pharmacology.

[4]  G. Maartens,et al.  High Prevalence of Subtherapeutic Plasma Concentrations of Efavirenz in Children , 2007, Journal of acquired immune deficiency syndromes.

[5]  M Schwab,et al.  Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV‐infected Individuals , 2007, Clinical pharmacology and therapeutics.

[6]  J. Beijnen,et al.  Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. , 2006, AIDS research and human retroviruses.

[7]  A. Vibhagool,et al.  Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results , 2006, AIDS.

[8]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[9]  J. Schapiro,et al.  Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. , 2006 .

[10]  M. Hirsch,et al.  Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. , 2005, The Journal of infectious diseases.

[11]  M. Eichelbaum,et al.  Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz , 2005, Pharmacogenetics and genomics.

[12]  K. Tashima,et al.  Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals , 2005, Annals of Internal Medicine.

[13]  A. Vibhagool,et al.  Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin , 2005, AIDS.

[14]  V. Soriano,et al.  Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Amalio Telenti,et al.  Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients , 2005, Pharmacogenetics and genomics.

[16]  F. van Leth,et al.  Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study , 2005, Antiviral therapy.

[17]  J. Beijnen,et al.  Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals , 2005, Clinical pharmacokinetics.

[18]  Catia Marzolini,et al.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.

[19]  S. Oka,et al.  Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. , 2004, Biochemical and Biophysical Research Communications - BBRC.

[20]  A. Sönnerborg,et al.  Efavirenz Plasma Concentrations in HIV-Infected Patients: Inter- and Intraindividual Variability and Clinical Effects , 2004, Therapeutic drug monitoring.

[21]  V. Soriano,et al.  Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  David A. Flockhart,et al.  The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[23]  F. Aweeka,et al.  Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS. , 2002, Journal of pharmaceutical and biomedical analysis.

[24]  J. Pachón,et al.  Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with Tuberculosis , 2002, Clinical pharmacokinetics.

[25]  V. Soriano,et al.  Higher efavirenz plasma levels correlate with development of insomnia. , 2001, Journal of acquired immune deficiency syndromes.

[26]  Michael D. Johnson,et al.  Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. , 2001, The Journal of pharmacology and experimental therapeutics.

[27]  A. Telenti,et al.  Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .

[28]  A. Wu,et al.  Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments , 2000, AIDS care.